The FDA has approved niraparib and abiraterone acetate with prednisone for the treatment of patients with BRCA2-mutated metastatic hormone-sensitive prostate cancer.
Welcome to Advanced Practice Corner
A space created exclusively for advanced practice providers in oncology. Here, you’ll find a wealth of resources tailored to your needs, including insightful articles, event information, a comprehensive resource guide, and educational videos.
Our mission is to support your vital role in cancer care by providing the latest advances in therapy options, adverse effect management, and patient communication strategies. This is your hub for the tools and knowledge to enhance your expertise and empower your practice.
Latest News
Advertisement
Subcutaneous daratumumab plus teclistamab improved survival outcomes in patients with R/R multiple myeloma vs standard daratumumab-based regimens.
Preoperative radiation and pembrolizumab improved T-cell infiltration in patients with higher-risk, HR-positive, HER2-negative, early-stage breast cancer.
Phase 2 data demonstrated similar pharmacokinetic profiles between subcutaneous azacitidine and an oral combination of azacitidine and cedazuridine.
The use of sacituzumab govitecan to treat HR+/HER2– metastatic breast cancer did not reach its primary end point of progression-free survival.
